Insider Cluster (2 insiders) ·Filed Mar 30, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $141K total
Actionable Insight • Neutral

Monitor for follow-up transactions—particularly from other C-suite executives—as isolated CFO selling paired with a small board buy is not strongly directional at this volume. No immediate catalyst is evident.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
DYN ▲ +20.60% at T+60d
NEUTRAL call ✓ call won +20.60% · α vs SPY +4.11% · entry $17.09 → $20.61
Entry anchored
Mar 27, 03:59 PM ET
via exchange tick
T+1d
+6.09%
call +6.09% · α +3.19%
$18.13
settled 6mo ago
T+5d
+6.26%
call +6.26% · α +1.96%
$18.16
settled 6mo ago
T+20d
+6.26%
call +6.26% · α -6.34%
$18.16
settled 5mo ago
T+60d
+20.60%
call +20.60% · α +4.11%
$20.61
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

A mixed insider trading cluster at Dyne Therapeutics shows CFO Erick Lucera selling $107K in shares while Director Brian Posner bought $34K, all within a 7-day window. The net selling by a C-suite executive outweighs the board-level purchase, but total volume remains below 0.1% of market cap.

Key Financial Metrics

Direction
mixed
Total Value
$140.9K
Insiders
2

Key Facts

  • CFO Erick Lucera sold 5,727 shares for $106,751 in open-market transactions on April 1, 2026.
  • Director Brian Posner purchased 2,000 shares for $34,160 on March 30, 2026.
  • Total cluster value is $140,911, representing just 0.0045% of Dyne Therapeutics' $3.1B market cap.
  • Net direction is mixed, with $107K in sales and $34K in purchases by corporate insiders.

Financial Impact

$141K total insider activity, net $73K in selling over 7 days

insider sentimentshareholder confidence

Risk Factors

  • CFO selling could signal caution ahead of a key clinical readout or financing need.
  • Low trade volume limits interpretive power; activity may be routine portfolio management.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-DYN-1775247052856
44 reports for DYN
Performance horizon
87% Hit rate 13 of 15 directional calls best @ T+60▲ +46.36%May 20, 2026
Filters
Rows
Reports for DYN — sortable, filterable
TypeNow
Aug 17, 2026
6w ago
Insider Cluster
BEARISH ★ 6/10
$26.15 $17.90▲ +31.55%▲ +29.57%$15.20 (+41.87%)
Aug 14, 2026
6w ago
144
NEUTRAL ★ 4/10
$26.15 $18.52▼ −29.18%▼ −27.65%$15.20 (−41.87%)
Aug 13, 2026
7w ago
144
BEARISH ★ 6/10
$25.70 $18.52▲ +27.94%▲ +25.95%$15.20 (+40.86%)
Aug 13, 2026
7w ago
144
NEUTRAL ★ 2/10
$25.70 $18.52▼ −27.94%▼ −25.95%$15.20 (−40.86%)
Aug 13, 2026
7w ago
144
NEUTRAL ★ 2/10
$25.70 $18.52▼ −27.94%▼ −25.95%$15.20 (−40.86%)
Jul 29, 2026
9w ago
Press Release
BULLISH ★ 7/10
$25.73 $26.09▲ +1.40%▼ −2.57%$15.20 (−40.92%)
Jul 22, 2026
10w ago
Press Release
BEARISH ★ 6/10
$23.21 $26.78▼ −15.38%▼ −12.48%$15.20 (+34.51%)
Jul 20, 2026
10w ago
8-K
BULLISH ★ 7/10
$23.45 $26.15▲ +11.51%▲ +7.39%$15.20 (−35.18%)
Jun 30, 2026
13w ago
Insider Cluster
NEUTRAL ★ 5/10
$21.79 $25.10▲ +15.19%▲ +17.38%$15.20 (−30.24%)
Jun 29, 2026
13w ago
144
BEARISH ★ 4/10
$22.21 $25.63▼ −15.40%▼ −16.43%$15.20 (+31.56%)
Showing 10 of 44

US Market Status

Market Closed — Opens Mon (65h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 3, 2026